Shares of medical device company Globus Medical (NYSE:GMED)
jumped 5.1% in the morning session after the company reported strong second-quarter financial results that surpassed Wall Street's expectations for both revenue and profit. The medical device company announced second-quarter worldwide net sales of $745.3 million, an 18.4% increase year-over-year, which topped analyst forecasts. Adjusted earnings per share landed at $0.86, comfortably beating the consensus estimate of $0.75. The results were supported by the ongoing integration of its 2023 acquisition of NuVasive, which expanded the company's global reach and product offerings in the spine technology market. Looking forward, Globus Medical reaffirmed its full-year 2025 guidance, projecting revenue around $2.85 billion and adjusted earnings per share of approximately $3.15, signaling confidence in its outlook.
Medical device company Globus Medical (NYSE:GMED) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 18.4% year on year to $745.3 million. The company expects the full year’s revenue to be around $2.85 billion, close to analysts’ estimates. Its non-GAAP profit of $0.86 per share was 14.1% above analysts’ consensus estimates.
Globus Medical (GMED) combines strong fundamentals—32% revenue growth, solid profitability, and zero debt—with a technical setup hinting at a potential breakout. A growth stock worth watching.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Globus Medical (GMED) offers strong growth, solid profitability, and fair valuation, making it an ideal GARP strategy pick for investors seeking balanced returns.
Shares of medical device company Globus Medical (NYSE:GMED)
fell 6.6% in the afternoon session after the unexpected resignation of its President and CEO, Daniel Scavilla.
Hitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
Globus Medical (NYSE:GMED) is a strong growth stock with solid fundamentals and a potential technical breakout, making it a candidate for investors seeking growth opportunities in the healthcare sector.
Globus Medical (NYSE:GMED) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth in the healthcare sector.
Shareholders of Globus Medical would probably like to forget the past six months even happened. The stock dropped 28.9% and now trades at $58.14. This was partly due to its softer quarterly results and might have investors contemplating their next move.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Looking back on medical devices & supplies - specialty stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers.
Medical device company Globus Medical (NYSE:GMED) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 1.4% year on year to $598.1 million. On the other hand, the company’s full-year revenue guidance of $2.85 billion at the midpoint came in 4.2% above analysts’ estimates. Its non-GAAP profit of $0.68 per share was 8.6% below analysts’ consensus estimates.
Globus Medical (NYSE:GMED) shows strong growth fundamentals and a technical setup suggesting a potential breakout. The stock combines revenue growth, profitability, and a favorable chart pattern.
GLOBUS MEDICAL (NYSE:GMED) is a strong growth stock with reasonable valuation, solid profitability, and a healthy balance sheet, making it an attractive option for investors seeking growth at a fair price.
Growth is oxygen.
But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle.
